An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer

Jia-Bin Wang,Ping Li,Xiao-Long Liu,Qiao-Ling Zheng,Yu-Bin Ma,Ya-Jun Zhao,Jian-Wei Xie,Jian-Xian Lin,Jun Lu,Qi-Yue Chen,Long-Long Cao,Mi Lin,Li-Chao Liu,Ning-Zi Lian,Ying-Hong Yang,Chang-Ming Huang,Chao-Hui Zheng
DOI: https://doi.org/10.1038/s41467-020-20260-7
IF: 16.6
2020-12-01
Nature Communications
Abstract:Abstract Immunosuppressive molecules are extremely valuable prognostic biomarkers across different cancer types. However, the diversity of different immunosuppressive molecules makes it very difficult to accurately predict clinical outcomes based only on a single immunosuppressive molecule. Here, we establish a comprehensive immune scoring system (ISS GC ) based on 6 immunosuppressive ligands (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44, and CD155) using the LASSO method to improve prognostic accuracy and provide an additional selection strategy for adjuvant chemotherapy of gastric cancer (GC). The results show that ISS GC is an independent prognostic factor and a supplement of TNM stage for GC patients, and it can improve their prognosis prediction accuracy; in addition, it can distinguish GC patients with better prognosis from those with high prognostic nutritional index score; furthermore, ISS GC can also be used as a tool to select GC patients who would benefit from adjuvant chemotherapy independent of their TNM stages, MSI status and EBV status.
multidisciplinary sciences
What problem does this paper attempt to address?
The problems that this paper attempts to solve are as follows: In patients with gastric cancer (GC), a single immunosuppressive molecule is difficult to accurately predict clinical outcomes. Therefore, researchers have established a comprehensive immune scoring system (Immune Scoring System for Gastric Cancer, ISS GC), based on six immunosuppressive ligands (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44, and CD155), using the LASSO method to improve prognostic accuracy and provide an additional strategy for selecting adjuvant chemotherapy. Specifically, the paper aims to: 1. **Improve the accuracy of prognostic assessment**: By integrating information from multiple immunosuppressive molecules, ISS GC can serve as an independent prognostic factor, supplementing TNM staging and improving the accuracy of prognostic prediction in gastric cancer patients. 2. **Distinguish patients with different prognoses**: ISS GC can distinguish the high - prognosis group and the low - prognosis group among gastric cancer patients with a higher Prognostic Nutritional Index (PNI) score. 3. **Guide the selection of adjuvant chemotherapy**: ISS GC can be used as a tool, independent of TNM staging, microsatellite instability (MSI) status, and Epstein - Barr virus (EBV) status, to select gastric cancer patients who may benefit from adjuvant chemotherapy. Through these goals, ISS GC can not only more accurately assess the prognosis of gastric cancer patients but also help doctors develop personalized treatment plans, thereby improving the long - term survival rate of patients.